Michael Su

First Affiliated Hospital of Henan University — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

33h-index10.4kcitations85works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(10), Cell death mechanisms and regulation(9), Acute Myeloid Leukemia Research(9), Computational Drug Discovery Methods(7), Epigenetics and DNA Methylation(7)

Publications84 total

NETosis-specific cell death: a novel mechanism in the pathogenesis of gouty arthritis
European journal of medical research·2025· 2 citedOpen Access
Next generation armored CAR-T cells with a drug inducible cytokine circuit
Theoretical and Natural Science·2023Open Access
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation
Nature Medicine·2023· 13 cited
Abstract 517: Targeting chromosomally unstable tumors with a selective KIF18A inhibitor
Cancer Research·2023· 1 cited
Discovery of potent, orally active KIF18A inhibitors targeting CIN-high cancer cells.
Journal of Clinical Oncology·2022· 3 cited
Author Correction: Risk factors for serious morbidity, prolonged length of stay and hospital readmission after laparoscopic appendectomy - results from Pol-LA (Polish Laparoscopic Appendectomy) multicenter large cohort study
Scientific Reports·2019· 4 citedOpen Access
Probing the acyl carrier protein–Enzyme interactions within terminal alkyne biosynthetic machinery
AIChE Journal·2018· 13 cited
Probing the Acyl Carrier Protein-Enzyme Interactions within Terminal Alkyne Biosynthetic Machinery
2018· 2 citedOpen Access
Beclin 2 CCD N187L mutant homodimer
2016
A fluorogenic screening platform enables directed evolution of an alkyne biosynthetic tool
Chemical Communications·2016· 17 cited
Bacterial Genome Mining of Enzymatic Tools for Alkyne Biosynthesis
ACS Chemical Biology·2015· 44 citedOpen Access
AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model
Annals of Oncology·2015· 2 cited
AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
Blood·2014· 48 cited
Abstract 963: IDH2(R140Q) knock-in mouse recapitulating human type II D-2-hydroxyglutaric aciduria
Cancer Research·2014
Abstract 1194: IDH1 mutant inhibitor induces cellular differentiation and offers a combination benefit with Ara-C in a primary human Idh1 mutant AML xenograft model
Cancer Research·2014· 3 cited
Abstract 3116: AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model
Cancer Research·2014· 6 cited
AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model
Blood·2013· 26 cited
IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model
Blood·2013· 13 cited
Table 1, Diaphorase/resazurin-coupled IDH1 R132H qHTS assay protocol
2013
Figure A2, LC-MS purity analysis for ML309
2013
page 1 of 5Next →

Frequent Co-authors

Yong Gu(9), Keisuke Kuida(7), Keith P. Wilson(7), David J. Livingston(5), Mark Fleming(5), Paul R. Caron(5), Marion Dorsch(5), Hua Yang(5), David P. Schenkein(5), Richard A. Flavell(4), Kathy Hsiao(4), Charles A. Dinarello(4), Ursula A. Germann(4), Ted Fox(4), Kim Straley(4), Janeta Popovici-Müller(4), Katharine Yen(4), Xuejun Zhu(4), Wenjun Zhang(4), Sung Choe(4)